RNAZ White background cropped.jpg
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
05 sept. 2024 07h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24 juil. 2024 04h00 HE | AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...
Emergen logo.png
Lung Cancer Therapeutics Market Size Worth USD 57.69 Billion in 2032 | Emergen Research
04 janv. 2024 07h45 HE | Emergen Research
Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global lung cancer therapeutics market size was USD 28.00 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.7% during the...
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
14 déc. 2023 04h00 HE | AKAMPION
YONGIN, South Korea, December 14, 2023 – 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
BioTech Breakthrough Awards Badge[1] copy.jpg
HistoSonics Edison System Recognized With BioTech Breakthrough Award For “MedTech Innovation Of The Year”
08 nov. 2023 08h02 HE | BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
purple-logo2020.png
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
03 oct. 2023 07h50 HE | Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab;  2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...
Transparency Market Research
Photodynamic Therapy Market to Grow at a CAGR of 13.5% from 2022 to 2031, reaching US$ 15.5 Billion: As per TMR Study
17 juil. 2023 15h30 HE | Transparency Market Research
Wilmington, Delaware, United States, July 18, 2023 (GLOBE NEWSWIRE) -- The global photodynamic therapy market stood at US$ 4.2 billion in 2021, and the global market is projected to reach US$ 15.5...
purple-logo2020.png
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
19 avr. 2023 08h15 HE | Purple Biotech Ltd.
New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...
TIP_link_300x300.jpg
Epirubicin Market Worth $243.99 Million, Globally, by 2028 at 3.6% CAGR - Exclusive Report by The Insight Partners
22 juil. 2022 06h56 HE | The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Epirubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Dosage (10mg/Vial,...
LOGO.jpg
Vivos Inc. Enhances its Intellectual Property Protection
24 févr. 2022 09h30 HE | Vivos Inc.
Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries. Our new patent team filed the...